Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Libtayo symbols : TEVJF save search
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
Published: 2022-09-12 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.78%
H: 0.58%
C: 0.58%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.55%
H: 0.43%
C: -1.33%
libtayo positive cell carcinoma
Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
Published: 2022-09-12 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.78%
H: 0.58%
C: 0.58%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.55%
H: 0.43%
C: -1.33%
libtayo melanoma response
ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers
Published: 2022-09-04 (Crawled : 00:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
libtayo potential
Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Published: 2022-08-03 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 4.36%
H: 3.91%
C: 1.46%
libtayo antibody cancer prostate cancer pd-1 inhibitor
Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab)
Published: 2022-07-01 (Crawled : 12:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.57%
H: 1.57%
C: 1.3%
libtayo
Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer
Published: 2022-06-02 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.55%
H: 0.0%
C: -0.12%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -2.18%
H: 0.0%
C: -3.71%
libtayo collaboration approved cancer sanofi pd-1 inhibitor
Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer
Published: 2022-01-28 (Crawled : 12:30) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.04%
H: 0.92%
C: 0.82%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.07%
H: 2.75%
C: 2.73%
libtayo cancer
FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC
Published: 2022-01-19 (Crawled : 13:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 1.84%
H: 1.79%
C: 0.18%
libtayo treatment fda therapy fda acceptance
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.